Pharmaceuticals & Therapeutics

Amid a record backlog and major program milestones, CEO Kathy Warden is set to detail the defense giant's strategy at Citi's upcoming tech and mobility event.

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

Radiation tech giant Mirion appoints three new executives, signaling a major strategic push into next-gen nuclear, advanced cancer care, and AI.

A new partnership with Uniphar will use managed access programs to provide the lymphoma therapy LYMPHIR to European patients with limited treatment options.

Amid a surging aerospace market, StandardAero's upcoming earnings report is highly anticipated after a year of record growth and strategic expansion.

As OneSpaWorld prepares its Q4 results, all eyes are on the wellness giant as a barometer for luxury travel spending and its tech-driven future.

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

South Korea's Hugel shatters sales records with a 105% surge in the Americas, signaling a major power shift in the global medical aesthetics market.

With FDA Priority Review, Takeda's oveporexton could be the first drug to target the root cause of narcolepsy, offering transformative hope for patients.

Laurie Ann Goldman, the branding guru who built SPANX, is now CEO of Audien Hearing. Can she make affordable hearing aids a mainstream wellness product?

NEXGEL has financing for a major acquisition, but the deal hinges on a critical due diligence phase. What does this mean for the hydrogel innovator?

FibroBiologics' Pete O'Heeron will speak at the H-SPAN summit, highlighting how cell therapy is driving a push for new healthspan legislation.

As Milestone Pharma launches its novel, self-administered heart drug CARDAMYST, it hires a legal expert to navigate the high-stakes commercial rollout.

Ahead of its first Climate Week, Mumbai's food innovators and activists gather to debate a sustainable future, proving the fight for the planet begins on our plates.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Enanta Pharmaceuticals unveils promising data for EDP-978, an oral drug targeting the root cause of conditions like chronic hives, asthma, and eczema.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

With transplant patient needs growing, BioMatrix promotes Heidi Ulbrich to manage its services, highlighting a model built for speed and complex care.